I can give you a concrete example of this.
There was a significant investment in AMR and bacterial diseases funding in the 1990s and early 2000s through something called the Canadian Bacterial Diseases Network, which was part of an investment in several network centres of excellence dedicated to certain disease areas or areas of biotechnology development, in partnership with small and large businesses. This was game-changing for a lot of folks like me, who were trying to build out their careers at this time. That program, unfortunately, sunsetted in the mid-2000s, leaving only CIHR able to make up that change. There are not a lot of other opportunities out there right now, and that's where our challenge lies.